Molecular and cellular pathophysiologic bases to the treatment of sikle cell disease;Bases physiopathologiques moléculaires et cellulaires du traitement de la drépanocytose

Hematologie

Volumn 2, Issue 6, 1996, Pages 499-510

  Elion, Jacques ^a   Labie, Dominique ^b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSTITUT COCHIN   (France)

Author keywords

Hemoglobin; Pathophysiology; Red blood cell; Sickle cell disease; Therapeutics

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

HUMAN; REVIEW; SICKLE CELL ANEMIA; THERAPY;

EID: 0030497773     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Pauling L, Itano HA, Singer SJ, Wells JC. Sickle cell aneinia : a molecular disease. Science 1949; 110 : 543-8.
2. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia haemoglobin. Nature 1956; 178: 792-4.
3. Wishner BC, Ward KB, Latiman EE, Love WE. Crystal, structure of sickle-cell dexyhemoglobin at 5Å resolution. J Mol Biol 1975 ; 98: 179-94.
4. Bunn HF. Sickle hemoglobin and other hemoglobin mutants. In : Stamatoyannopoulos G, Nienhuis AW, Majerus FW, Varmus H, eds. The Molecular basis of blood diseases, 2nd ed. Philadelphia: Sounders, 1994: 207-56.
5. Charache S, Terrin ML, Moore RO, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995 ; 332 : 1317-22.
6. Ley TJ. The pharmacology of hemoglobin switching: of mice and men. Blood 1991 ; 77: 1146-52.
7. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993 ; 81 : 1109-23.
8. Vermylen C, Cornu G. Bone marrow transplantation for sickle-cell disease : the European experience. Am J Pedioir Hematol Oncol 1994 ; 16 : 18-21.
9. Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia - The dilemna of choice. N Engl J Med 1996 ; 335 : 426-8.
10. Nalbandian RM, Henry RL. Urea and the sickle cell crisis. J Am Med Assoc 1974 ; 229 : 1285.
11. Harkness DR, Roth S. Clinical evaluation of cyonate in sickle cell anemia. Prog Hematol 1975; 9: 157-84.
12. Orringer EP, Abraham DJ, Parker JC. Development of drug therapy. In : Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle cell disease: basic principles and clinical practice. New York: Raven press, 1994 : 861-71.
13. Rosa RM, Bierer BE, Bunn HF, Epstein FH. The treatment of sickle cell anemia with induced hyponatremia. Blood Cells 1980; 8: 329-35.
14. Sablayrolles M, Wajcman H, Castaigne JP, Labie D. Membrane expansion as a mechanism explaining the antisickling action of ticlopidine observed in vitro. Am J Hematol 1985; 18; 121-30.
15. Rodgers GP, Roy MS, Noguchi CT, Schechter AN. Is there a role for selective vasodilation in the management of sickle cell disease? Blood 1988 ; 71 : 597-602.
16. Watson J, Stahman AW, Bilello FP. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 1948 ; 215 : 419.
17. Serjeant GR. Fetal hemoglobin in homozygous sickle cell disease. Clin Haematol 1975 ; 4 : 109-22.
18. Pembrey ME, Wood WG, Weatherall DJ, Perrine RP. Fetal hemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia. Br J Haematol 1978 ; 49 : 415-29.
19. Sunshine HR, Hofrichter J, Eaton WA. Gelation of sickle cell hemoglobin in mixtures with normal and fetal hemoglobins. J Mol Biol 1978 ; 133 : 435-67.
20. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiological ligand saturations, Proc Natl Acad Sci USA 1993; 90 : 5039-43.
21. De Ceulaer K, Gruber C, Hayes RJ, Serjeant GR. Medroxyprogesierone acetate ana homozygous sickle cell disease. Lancet 1982; 2: 229-31.
22. Arapinis C, Elion J, Labie D, Krishnamoorthy R. Differences in Dnase I sensifivity and methylation within the human-β-globin gene domain and correlation with expression. Eur Biochem 1986; 156: 123-9.
23. Enver T, Zhang JW, Papayannopoulou T, Stamatoyannopoulos G. DNA methylation : a secondary event in globin gene switching? Genes & Dev 1988 ; 2 : 698-706.
24. DeSimone J, Heller P, Hall I, Zwiers D. 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982 ; 79 : 4428-31.
25. + thalassemia. N Engl J Med 1982; 307: 1409-75.
26. Charache S, Dover G, Smith K, Talbot CC, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γ-δ-β globin gene complex. Proc Natl Acad Sci USA 1983; 80: 4842-6.
27. Galanello R, Stamatoyannopoulos G, Papayannopoulou T. Mechanism of Hb F stimutation by S-stage compounds. J Clin Invest 1988; 81: 1209-10.
28. Letvin NL, Linch DC, Beardsley P, McIntyre KW, Nathan DG. Augmentation of fetal hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984; 310: 869-73.
29. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652-6.
30. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea treatment in children severely affected with sickle cell disease. J Pediatr 1996; 128: 820-8.
31. de Montalembert M, Belloy M, Bernaudin F, Ducrocq R, Maier-Redelsperger M, Philippe N, Schechter AN, Girot R. Clinical and hemotological response of sickle cell children treatment with hydroxyurea. Blood 1994; 84 (suppl. 1): 219a.
32. Milner P, Kutlar A, Pantazis C, Nagel RN. Hemoglobin F response in sickle cell anemia to a constant daily dose of Hydroxyurea without escalation to maximal tolerated dose. 19th annual meeting of the national sickle cell disease program. New York City; March 23-26, 1994.
33. Rodgers GP, Dover GJ, Nóguchi CT, Schlechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990; 322: 1037-45.
34. Maier-Redelsperger M, de Montalembert M, Ducrocq R, Belloy M, Bemavdin F, Elion J, Labie D, Schechter AN, Girot R. Fetal hemoglobin evolution and cellular parameters during hydroxyurea treatment of young sickle cell patients. 20th Annual meeting of the national sickle cell program. Boston, March 18-21, 1995: 196.
35. Stamatoyannopoulos G, Veith R, Galanello R, Papayannopoulou T. Hb F production in stressed erythropoiesis : observations and kinetic models. Ann NY Acad Sci 1985; 445: 188-97.
36. Labie D. Effets pléïotropiques de l'hydroxyurée. médecine/sciences 1994; 10: 1036.
37. Orringer EP, Blythe DSB, Johnson AE, Phillips J, Dover GJ, Parker JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 1991; 78: 212-6.
38. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Cnarache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engt J Med 1990; 323: 366-72.
39. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, Mangahas L, Abel R, Stamatoyannopoulos G. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood 1993; 81: 9-14.
40. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993; 328: 73-80.
41. Pemne SP, Greene MF, Faller DV. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 1985; 312: 334-8.
42. Kruh J, Defer N, Tichonicky L. Effects of butyrate on cell proliferation and gene expression. In: Physiological and clinical aspects of short-chain fatty acids. Cambridge: University Press, 1995: 275-88.
43. Perrine SP, Rudolph A, Faller DV, Roman C, Cohen RA, Chen SJ, Kan YVV. Bulyrate infusions in the ovine fetvs delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA 1988; 85: 8540-2.
44. Burns IJ, Glauber JG, Ginder GD. Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in aduli erythroid cells. Blood 1988; 72: 1536-42.
45. Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrotes : in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 1989; 74: 1963-71.
46. Fibach E, Prasanna P, Rodgers GP, Samid D, Enhanced fetal hemoglobin production by phenylacetote and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-tholassemia. Blood 1993; 82. 2203-9.
47. Ginder DG, Whitters JM, Pohlman KJ. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. proc Natl Acad Sci USA 1984; 81: 3954-8.
48. Aγ gene promoter mutants. Blood 1990; 88: 1079-83.
49. Perrine SP, Ginder GD, Faller DV, DoverGH, Ikuta T. Wrtkowska HE, Cai SP, Vichinsky EP, Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993; 328: 81-6.
50. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 1992; 327: 569-70.
51. Perrine SP, Dover GH, Daftari P, Walsh CT, Jin YX, Mays A, Faller DV. Isobutyramide, an orally available butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. Br J Haematol 1994; 88: 555-61.
52. Collins AF, Dover GJ, Luban NLC. Increased fetal hemoglobin in patients receiving valproic acid for epilepsy. Blood 1994; 84: 1690-1.
53. Stamatoyannopoulos G, Blau CA, Nakamoto B, Josephson B, Li Q, Liakopoulou E, Pace B, Papayannopoulou T, Brusilow SVV, Dover G. Fetal hemoglobin induction by acetate, a product of butyrate catobolism. Blood 1994; 84: 3198-204.
54. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf JA, Fournarakis B, Raisys V, Dover G, Papayannopoulou T, Stamatoyannopoulos G. Stimulation of fetal hemoglobin by short chain fatly acids. Blood 1995; 86: 3227-35.
55. Glauber JG, Wandersee NJ, Little JA, Ginder GD. 5′-ftanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells. Mol Cell Biol 1991; 11: 4690-7.
56. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991; 77: 214-37.
57. Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991; 77: 1405-14.
58. Setty BNY, Stuart MJ,. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996; 88: 2311-20.
59. Lobie D, Elion J. Modulation polygénique des maladies monogéniques: l'exemple de la drépanocytose. médecine/sciences 1996; 12: 341-9.
60. + transport and reverses erythrocyte dehydration in transgenic SAD mice. J Clin Invesl 1994; 93: 1670-6.
61. Shalev O, Hebbel RP. Catalysis of soluble hemoglobin oxidation by free iron on sickle red cell membrane. Blood 1996; 87: 3948-52.
62. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri N. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one [L1] in ironloaded patients with sickle cell disease. Blood 1994; 83: 2329-33.
63. Shalev O, Hebbel RP. Extremely high avidity association of Fe[III] with the sickle red cell membrane. Blood 1996; 88: 349-52.
64. Dias-da-Motta PM, Arruda VR, Muscara MN, Saad STO, De Nucci G, Costa FF, Condino-Neto A. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anemia. Br J Haematol 1996; 93: 333-40.
65. Poyart C, Bursaux E. L'hémoglobine, le NO, les complexes protéiques nitrosylés et la régulation de la pression vasculaire. médecine/sciences 1996; 12: 848-50.
66. Greaves DR, Fraser P, Vidai MA, Hedges MJ, Ropers D, Luzzatto L, Grosveld F. A transgenic mouse model of sickle cell disorder. Nature 1990; 343: 183-5.
67. Detloff PJ, Lewis J, John SWM, Shehee WR, langenbach R, Maeda N, Smithies O. Deletion and replacement of the mouse adult β-globin genes by a «plug and socket »repeated targeting strategy Mol Cell Biol 1994; 14: 6930-43.
68. Trudel M, De Paepe ME, Chrétien N, Saadane N, Jacmain J, Sorette M, Hoang T, Beuzard Y. Sickle cell disease of transgenic SAD mice. Blood 1994; 84: 3189-97.
69. Nagel RL. Lessons from transgenic mouse lines expressing sickle hemoglobin. Proc Soc Exp Biol Med 1994; 205: 274-81.
70. Peterson KR, Clegg CH, Huxley C, Josephson BM, Haugen HS, Furukacia T, Stammatoyannopouls G. Transgenic mice containing a 248kb human β-locus yeast artificial chromosome display proper developmental control of human globin genes. Proc Natl Acad Sci USA 1993; 90: 7593-7.
71. Ronchi A, Berry M, Raguz S, Iham A, Yannoutsos N, Ottolenghi S, Grosveld F, Dillon N. Role of the duplicated CCAAT box region in γ-globin gene regulation and hereditary persistence of foetal haemoglobin. EMBO J 1996; 15: 143-9.
72. Cole-Strauss A, Yoon K, Xiang Y, Burne BC, Rice MC, Gryn J. Holloman WK, Kmies EB. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 1996; 273: 1386-9.